{
  "ticker": "RHY",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959944",
  "id": "02959944",
  "pages": 30,
  "price_sensitive": false,
  "date": "20250619",
  "time": "0912",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250619/pdf/06kwvn6060sjhk.pdf",
  "summary": "No material information identified.  \n*(The document appears to be a promotional overview/deck with no new updates on financings, operations, or material events. Summary not required for trading or capital markets decisions.)*  \n\n**Key Context (Non-Material):**  \n- Commercial focus: geneTypeTM (available), ColoSTAT\u00ae (expected 2H 2025).  \n- Market opportunity: >$50bn global cancer screening.  \n- Cash balance (31 Mar 2025): AUD $2.3M.  \n\n*Note: Omitted operational/growth targets, pipeline details, and market sizing as they are forward-looking and non-material per guidelines.*",
  "usage": {
    "prompt_tokens": 5386,
    "completion_tokens": 136,
    "total_tokens": 5522,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-18T23:33:11.672966"
}